<i>In Vitro</i> Activity of Proveblue (Methylene Blue) on Plasmodium falciparum Strains Resistant to Standard Antimalarial Drugs

Aurélie Pascual, Maud Henry, Sébastien Briolant, Serge Charras, Eric Baret, Rémy Amalvict, Emilie Huyghues des Etages, Michel Féraud, Christophe Rogier, Bruno Pradines

Antimicrobial Agents and Chemotherapy · 2011 · 46 citations · 23 references

DOIFull text

Open access

Concepts

Abstract

The geometric mean 50% inhibitory concentration (IC50) for Proveblue, a methylene blue complying with the European Pharmacopoeia, was more active on 23 P. falciparum strains than chloroquine, quinine, mefloquine, monodesethylamodiaquine, and lumefantrine. We did not find significant associations between the Proveblue IC50 and polymorphisms in the pfcrt, pfmdr1, pfmdr2, pfmrp, and pfnhe-1 genes or the copy numbers of the pfmdr1 and pfmdr2 genes, all of which are involved in antimalarial resistance.

References

23